Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Leiomyosarcoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × rubitecan × Gastrointestinal × Clear all
NCT00113256 2024-08-02

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Astex Pharmaceuticals, Inc.

Phase 2/3 Terminated
39 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡